Frontlight ResearchEarly access
Neuroendocrine tumours trials in Austria
3 of 4 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in AustriaDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
- Where
- Graz, Vienna
- Age
- 18 years and over
- People
- 390 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00 - Phase 2/3Taking peopleZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Where
- Graz, Salzburg, Vienna
- Age
- 18 years and over
- People
- 440 worldwide
- Run by
- Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00 - Phase 3Active, not recruitingStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Graz, Krems An Der Donau
- Age
- 18 years and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00